Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02625610
Registration number
NCT02625610
Ethics application status
Date submitted
4/12/2015
Date registered
9/12/2015
Date last updated
9/06/2022
Titles & IDs
Public title
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
Query!
Scientific title
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Query!
Secondary ID [1]
0
0
2015-003300-23
Query!
Secondary ID [2]
0
0
EMR 100070-007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Avelumab
Treatment: Drugs - Oxaliplatin
Treatment: Drugs - 5-Fluorouracil
Treatment: Drugs - Leucovorin
Treatment: Drugs - Capecitabine
Other interventions - Best supportive care
Treatment: Drugs - Oxaliplatin
Treatment: Drugs - 5-Fluorouracil
Treatment: Drugs - Leucovorin
Treatment: Drugs - Capecitabine
Experimental: Chemotherapy + Best Supportive Care (BSC) - In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.
Experimental: Avelumab - In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.
Treatment: Drugs: Avelumab
Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
Treatment: Drugs: Oxaliplatin
Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Treatment: Drugs: 5-Fluorouracil
Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Treatment: Drugs: Leucovorin
Induction Phase: Leucovorin was administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Treatment: Drugs: Capecitabine
Induction Phase: Capecitabine was administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Other interventions: Best supportive care
Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
Treatment: Drugs: Oxaliplatin
Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
Treatment: Drugs: 5-Fluorouracil
Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
Treatment: Drugs: Leucovorin
Induction Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Treatment: Drugs: Capecitabine
Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall Survival was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [1]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS) by Independent Review Committee (IRC)
Query!
Assessment method [1]
0
0
The PFS time was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurs first). PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as per IRC. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Query!
Timepoint [1]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Secondary outcome [2]
0
0
Best Overall Response (BOR) by Investigator Assessment
Query!
Assessment method [2]
0
0
BOR was determined by RECIST v1.1 per Investigator assessment and defined as best-confirmed response of any of following: complete response (CR), partial response (PR), stable disease (SD) and PD recorded from date of randomization until disease progression or recurrence. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in SLD of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or appearance of 1 or more new lesions. PR or CR confirmed at a subsequent tumor assessment, not sooner than 5 weeks after initial documentation or at an assessment later than the next assessment after the initial documentation of PR or CR. SD confirmed at least 6 weeks after randomization. Confirmed PD equal to progression <=2 weeks after date of randomization.
Query!
Timepoint [2]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Secondary outcome [3]
0
0
Objective Response Rate (ORR) by Investigator Assessment
Query!
Assessment method [3]
0
0
The ORR defined as the percentage of all randomized participants with a confirmed best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1 and as per Investigator assessment. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.
Query!
Timepoint [3]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Secondary outcome [4]
0
0
Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)
Query!
Assessment method [4]
0
0
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall composite health state index score, with scores ranging from -0.594 to 1. A higher score indicates better health state.
Query!
Timepoint [4]
0
0
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Query!
Secondary outcome [5]
0
0
Change From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)
Query!
Assessment method [5]
0
0
EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
Query!
Timepoint [5]
0
0
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Query!
Secondary outcome [6]
0
0
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)
Query!
Assessment method [6]
0
0
European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Query!
Timepoint [6]
0
0
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Query!
Secondary outcome [7]
0
0
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)
Query!
Assessment method [7]
0
0
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) supplements the EORTC QLQ-C30 to assess symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
Query!
Timepoint [7]
0
0
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Query!
Secondary outcome [8]
0
0
Maintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
Query!
Assessment method [8]
0
0
Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.
Query!
Timepoint [8]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Secondary outcome [9]
0
0
Maintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values
Query!
Assessment method [9]
0
0
Blood samples were collected for the analysis of following hematology parameters: lymphocyte count, neutrophil count, white blood cells, platelet count, lipase, serum amylase, creatinine phosphokinase and creatinine. The hematology parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case (Grade 4) post Baseline is presented. Only those participants with increase to grade 4 have been presented.
Query!
Timepoint [9]
0
0
From baseline up to 1276 days
Query!
Secondary outcome [10]
0
0
Maintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
Query!
Assessment method [10]
0
0
Vital signs assessment included Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and Pulse Rate (PR). Number of Participants with any potentially clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.
Query!
Timepoint [10]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Secondary outcome [11]
0
0
Maintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Query!
Assessment method [11]
0
0
ECG parameters included heart rate, pulse rate intervals, QRS interval, QT interval corrected based on Fridericia's formula (QTcF) intervals and QTcB intervals. Clinical significance was determined by the investigator. Number of participants with potentially clinically significant ECG abnormalities were reported.
Query!
Timepoint [11]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Secondary outcome [12]
0
0
Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1
Query!
Assessment method [12]
0
0
ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with shift in ECOG PS Score to 1 or Higher Than 1 were reported.
Query!
Timepoint [12]
0
0
From randomization into maintenance phase up to 1276 days
Query!
Eligibility
Key inclusion criteria
- Male or female participants greater than or equal to (>=) 18 years
- Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1
(RECIST 1.1)
- Participants with histologically confirmed unresectable locally advanced or metastatic
adenocarcinoma of the stomach or gastro-esophageal junction (GEJ)
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial
entry
- Estimated life expectancy of more than 12 weeks
- Adequate haematological, hepatic and renal functions defined by the protocol
- Negative blood pregnancy test at Screening for women of childbearing potential
- Highly effective contraception for both male and female participants if the risk of
conception exists
- Other protocol defined inclusion criteria could apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior therapy with any antibody or drug targeting T-cell coregulatory proteins
- Concurrent anticancer treatment or immunosuppressive agents
- Prior chemotherapy for unresectable locally advanced or metastatic adenocarcinoma of
the stomach or gastro-esophageal junction (GEJ)
- Tumor shown to be human epidermal growth factor 2 plus (HER2+)
- Major surgery for any reason, except diagnostic biopsy, within 4 weeks of enrolment
and/or if the participant has not fully recovered from the surgery within 4 weeks of
enrolment
- Participants receiving immunosuppressive agents (such as steroids) for any reason
should be tapered off these drugs before initiation of the study treatment (with the
exception of participants with adrenal insufficiency, who may continue corticosteroids
at physiologic replacement dose, equivalent to <= 10 mg prednisone daily)
- All participants with brain metastases, except those meeting the following criteria:
a. Brain metastases have been treated locally, have not been progressing at least 2
months after completion of therapy, and no steroid maintenance therapy is required,
and b. No ongoing neurological symptoms that are related to the brain localization of
the disease (sequelae that are a consequence of the treatment of the brain metastases
are acceptable)
- Previous malignant disease (other than gastric cancer) within the last 5 years with
the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ
(bladder, cervical, colorectal, breast)
- Prior organ transplantation, including allogeneic stem-cell transplantation
- Significant acute or chronic infections
- Active autoimmune disease that might deteriorate when receiving an immunostimulatory
agent
- Known severe hypersensitivity reactions to monoclonal antibodies, any history of
anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially
controlled asthma)
- Persisting toxicity related to prior therapy except alopecia
- Neuropathy Grade > 3
- Pregnancy or lactation
- Known alcohol or drug abuse
- History of uncontrolled intercurrent illness including hypertension, active infection,
diabetes
- Clinically significant (i.e., active) cardiovascular disease
- All other significant diseases might impair the participant's tolerance of study
treatment
- Any psychiatric condition that would prohibit the understanding or rendering of
informed consent and that would limit compliance with study requirements
- Vaccination with live or live/attenuated viruses within 55 days of the first dose of
avelumab and while on trial is prohibited except for administration of inactivated
vaccines
- Legal incapacity or limited legal capacity
- Participants will be excluded from the Induction Phase and the Maintenance Phase if
administration of their chemotherapy would be inconsistent with the current local
labelling (SmPC) (e.g., in regard to contraindications, warnings/precautions or
special provisions) for that chemotherapy. Investigators should check updated
labelling via relevant websites at the time of entry into the Induction Phase and the
Maintenance Phase
- Other protocol defined exclusion criteria could apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/12/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
3/06/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
499
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
St George Hospital - Kogarah
Query!
Recruitment hospital [2]
0
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [3]
0
0
Greenslopes Private Hospital - Greenslopes
Query!
Recruitment hospital [4]
0
0
Royal Brisbane and Women's Hospital - Herston
Query!
Recruitment hospital [5]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [6]
0
0
Lyell McEwin Hospital - Elizabeth Vale
Query!
Recruitment hospital [7]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [8]
0
0
Ballarat Base Hospital - Ballarat
Query!
Recruitment hospital [9]
0
0
Bendigo Hospital - Bendigo
Query!
Recruitment hospital [10]
0
0
Monash Medical Centre Clayton - Bentleigh
Query!
Recruitment hospital [11]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [12]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [13]
0
0
Border Medical Oncology - Wodonga
Query!
Recruitment hospital [14]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [4]
0
0
4006 - Herston
Query!
Recruitment postcode(s) [5]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [6]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [7]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [8]
0
0
3350 - Ballarat
Query!
Recruitment postcode(s) [9]
0
0
3550 - Bendigo
Query!
Recruitment postcode(s) [10]
0
0
8120 - Bentleigh
Query!
Recruitment postcode(s) [11]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [12]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [13]
0
0
3690 - Wodonga
Query!
Recruitment postcode(s) [14]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nevada
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oregon
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Rhode Island
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
South Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Bahia
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Rio Grande Do Sul
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Sao Paulo
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Badajoz
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Nova Scotia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Ontario
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Quebec
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Alpes Maritimes
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Bouches Du Rhone
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Brittany
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Côte-d'Or
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Doubs
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Gironde
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Haute Garonne
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Ille Et Vilaine
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Indre Et Loire
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Maine Et Loire
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Paris
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Puy De Dome
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Sarthe
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Baden Wuerttemberg
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Bayern
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hessen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Rheinland Pfalz
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Hamburg
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Baranya
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Gyor-Moson-Sopron
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Hajdú-Bihar
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Budapest
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Nyiregyhaza
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Szekszard
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Szolnok
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Zalaegerszeg
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Catania
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Cremona
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Firenze
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Milano
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Napoli
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Padova
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Rimini
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Roma
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Terni
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Udine
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Chiba-Ken
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Kagawa-Ken
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Kanagawa-Ken
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Kumamoto-Ken
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Miyagi-Ken
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Niigata-Ken
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Oita-ken
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Osaka-Fu
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Osaka
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Saitama-Ken
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Tochigi-Ken
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Tokyo-To
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Kagoshima-shi
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Chungcheongbuk-do
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Gyeonggi-do
Query!
Country [76]
0
0
Korea, Republic of
Query!
State/province [76]
0
0
Jeollanam-do
Query!
Country [77]
0
0
Korea, Republic of
Query!
State/province [77]
0
0
Jung-gu
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Busan
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Daegu
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Seoul
Query!
Country [81]
0
0
Romania
Query!
State/province [81]
0
0
Cluj
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Dolj
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Prahova
Query!
Country [84]
0
0
Romania
Query!
State/province [84]
0
0
Timis
Query!
Country [85]
0
0
Romania
Query!
State/province [85]
0
0
Baia Mare
Query!
Country [86]
0
0
Romania
Query!
State/province [86]
0
0
Bucuresti
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Iasi
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Leningrado
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Arkhangelsk
Query!
Country [90]
0
0
Russian Federation
Query!
State/province [90]
0
0
Chelyabinsk
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
Ivanovo
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Krasnodar
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Moscow
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Omsk
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Pyatigorsk
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Saint-Petersburg
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Alicante
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Barcelona
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Madrid
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Sevilla
Query!
Country [101]
0
0
Taiwan
Query!
State/province [101]
0
0
Kaohsiung
Query!
Country [102]
0
0
Taiwan
Query!
State/province [102]
0
0
Taichung
Query!
Country [103]
0
0
Taiwan
Query!
State/province [103]
0
0
Tainan
Query!
Country [104]
0
0
Taiwan
Query!
State/province [104]
0
0
Taipei
Query!
Country [105]
0
0
Taiwan
Query!
State/province [105]
0
0
Taoyuan
Query!
Country [106]
0
0
Thailand
Query!
State/province [106]
0
0
Bangkok
Query!
Country [107]
0
0
Thailand
Query!
State/province [107]
0
0
Chiang Mai
Query!
Country [108]
0
0
Turkey
Query!
State/province [108]
0
0
Adana
Query!
Country [109]
0
0
Turkey
Query!
State/province [109]
0
0
Ankara
Query!
Country [110]
0
0
Turkey
Query!
State/province [110]
0
0
Antalya
Query!
Country [111]
0
0
Turkey
Query!
State/province [111]
0
0
Diyarbakir
Query!
Country [112]
0
0
Turkey
Query!
State/province [112]
0
0
Istanbul
Query!
Country [113]
0
0
Turkey
Query!
State/province [113]
0
0
Kocaeli
Query!
Country [114]
0
0
Turkey
Query!
State/province [114]
0
0
Konya
Query!
Country [115]
0
0
Turkey
Query!
State/province [115]
0
0
Malatya
Query!
Country [116]
0
0
Turkey
Query!
State/province [116]
0
0
Mersin
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Devon
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Greater London
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Greater Manchester
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Merseyside
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Middlesex
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Surrey
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Tayside Region
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
West Yorkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
EMD Serono Research & Development Institute, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Merck KGaA, Darmstadt, Germany
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study was to demonstrate superiority of treatment with avelumab versus
continuation of first-line chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02625610
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Responsible
Query!
Address
0
0
EMD Serono Research & Development Institute, Inc. a business of Merck KGaA, Darmstadt, Germany
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02625610
Download to PDF